News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
683,086 Results
Type
Article (38964)
Company Profile (276)
Press Release (643846)
Section
Business (203820)
Career Advice (1985)
Deals (35357)
Drug Delivery (84)
Drug Development (80768)
Employer Resources (168)
FDA (16085)
Job Trends (14796)
News (344461)
Policy (32429)
Tag
Academia (2530)
Alliances (49035)
Alzheimer's disease (1214)
Approvals (16003)
Artificial intelligence (114)
Bankruptcy (352)
Best Places to Work (11461)
Biotechnology (196)
Breast cancer (104)
Cancer (894)
Cardiovascular disease (79)
Career advice (1656)
Cell therapy (195)
Clinical research (63906)
Collaboration (321)
Compensation (167)
COVID-19 (2522)
Cystic fibrosis (78)
Data (847)
Diabetes (132)
Diagnostics (6093)
Earnings (84105)
Employer resources (146)
Events (108779)
Executive appointments (239)
FDA (16520)
Funding (287)
Gene therapy (147)
GLP-1 (556)
Government (4316)
Healthcare (18650)
Infectious disease (2595)
Inflammatory bowel disease (101)
Interviews (308)
IPO (16263)
Job creations (3622)
Job search strategy (1415)
Layoffs (407)
Legal (7847)
Lung cancer (154)
Manufacturing (149)
Medical device (13144)
Medtech (13149)
Mergers & acquisitions (19103)
Metabolic disorders (354)
Neuroscience (1452)
NextGen Class of 2024 (6494)
Non-profit (4462)
Northern California (1186)
Obesity (210)
Opinion (176)
Patents (94)
People (56108)
Phase I (19818)
Phase II (28136)
Phase III (21011)
Pipeline (206)
Postmarket research (2553)
Preclinical (8423)
Radiopharmaceuticals (234)
Rare diseases (178)
Real estate (5888)
Regulatory (21433)
Research institute (2307)
Resumes & cover letters (349)
Southern California (1070)
Startups (3560)
United States (11489)
Vaccines (535)
Weight loss (156)
Date
Today (91)
Last 7 days (729)
Last 30 days (2694)
Last 365 days (35628)
2024 (30191)
2023 (40074)
2022 (51173)
2021 (55713)
2020 (54087)
2019 (46541)
2018 (35019)
2017 (32110)
2016 (31480)
2015 (37552)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (713)
Arizona (186)
Asia (37004)
Australia (6035)
California (2683)
Canada (1164)
China (208)
Colorado (117)
Connecticut (119)
Europe (79208)
Florida (388)
Georgia (98)
Illinois (306)
Indiana (176)
Kansas (95)
Maryland (512)
Massachusetts (2174)
Michigan (142)
Minnesota (246)
New Jersey (814)
New York (828)
North Carolina (658)
Northern California (1186)
Ohio (125)
Pennsylvania (739)
South America (1091)
Southern California (1070)
Texas (377)
Utah (79)
Washington State (318)
683,086 Results for "nephrosant inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Biotech Bay
NephroSant Launches Two-Year Study of 2,000 Kidney Transplant Recipients
NephroSant™, Inc. a biotechnology company dedicated to accelerating the assessment of early kidney damage with a mission to significantly improve global kidney health, announced the first patient has been enrolled into the Assessment of QSant™ for Underlying Allograft Rejection study.
March 21, 2022
·
4 min read
Biotech Bay
NephroSant Features QSant, the first urine test for kidney transplant rejection, at Biotech Showcase Digital 2022
NephroSant, Inc. a biotechnology company dedicated to accelerating the diagnosis of early kidney damage in native and transplanted kidneys, with a mission to significantly improve global kidney health, announced that it will present a company overview at the upcoming Biotech Showcase conference.
January 3, 2022
·
4 min read
Biotech Bay
NephroSant Publishes Real-World Evidence Showing Potential to Improve the Detection of Early Rejection Events with QSant
NephroSant™ announced that the Journal of Clinical Medicine has published real-world data (RWD) that provides insight into how changes in allograft health are reflected in specific ranges of QSant™ scores.
March 3, 2022
·
4 min read
Biotech Bay
NephroSant Executives Recognized for Contributions to Transplant Care and Advocacy by Prestigious Industry Groups
Dr. Minnie Sarwal, NephroSant Founder, selected as winner of Lyfebulb-CSL Behring Innovation Challenge: Thriving with Transplantation NephroSant Head of Marketing Maria Lopes honored with the Maciak Award at the 2020 Transplant Games of America.
August 16, 2021
·
3 min read
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
2 min read
·
Voyager Therapeutics, Inc.
Press Releases
Verrica Pharmaceuticals Announces Litigation Settlement with Dormer Laboratories, Inc.
Verrica Pharmaceuticals Inc. today announced the settlement of litigation with Dormer Laboratories, Inc. (“Dormer Labs”).
July 1, 2024
·
5 min read
Lophos Holdings Inc. Announces the Completion of Securities Purchase Agreement with ThreeD Capital Inc.
Lophos Holdings Inc. (CSE: MESC) (“Lophos” or the “Company”), a Canadian bioscience company focused on the cultivation and sale of Lophophora williamsii (“Peyote”) and ThreeD Capital Inc. (CSE: IDK) (OTCQB: IDKFF) (“ThreeD”), a Canadian-based venture capital firm focused on opportunistic investments in companies in the junior resources and disruptive technologies sectors, are pleased to announce the completion of its previously announced Securities Purchase Agreement (the “Agreement”).
June 20, 2024
·
4 min read
Press Releases
Virios Therapeutics, Inc. and Wex Pharmaceuticals, Inc. Announce Business Combination to Form Dogwood Therapeutics, Inc. (Nasdaq: “DWTX”)
October 8, 2024
·
14 min read
Vivos Inc. Submits the Application to the FDA for Authority to Initiate Human Clinical Trials
Vivos Inc. (OTCQB: RDGL), Vivos Inc. filed the application for an Investigational Device Exemption (“IDE”).
June 28, 2024
·
4 min read
Press Releases
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) and HOPE Therapeutics, Inc. Announce Participation at the ThinkEquity Conference October 30, 2024
October 24, 2024
·
4 min read
1 of 68,309
Next